Accessibility Menu
Precision BioSciences logo

Precision BioSciences(NASDAQ) DTIL

Current Price$7.32
Market Cap$188.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-99%
5 Year-98%
1 Year+51%
1 Month+3%
Precision BioSciences last closing stock price
MetricPriceDate
Last closeUSD 7.322026-07-22
Precision BioSciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.91%USD 8.812026-07-15
1 month+3.39%USD 7.082026-06-22
3 month+0.14%USD 7.312026-04-23
Year to date+75.96%USD 4.162025-12-31
1 year+50.62%USD 4.862025-07-22
3 year-61.93%USD 19.232023-07-21
5 year-97.62%USD 307.502021-07-23
Since inception-98.6%USD 523.202019-03-28

Precision BioSciences Financials at a Glance

Market Cap

$188.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$45.07M

Net Income (TTM)

-$43.60M

EPS (TTM)

-$3.72

P/E Ratio

-1.97

Dividend

$0.00

Beta (Volatility)

1.33 (Average)

Price

$7.32

Volume

1

Open

$7.54

Previous Close

$7.32

Daily Range

$7.21 - $7.59

52-Week Range

$3.53 - $9.62

Estimated Earnings Date

Aug 6, 2026

DTIL News

Foolcom-Featured.png

DTIL Revenue Drops 99%

Motley Fool Markets TeamAug 7, 2025
433 money grab

Don't Waste Your Money on Penny Stocks, These 2 Stocks Are Better Buys

Maxx ChatskoApr 17, 2020
302 yellow airplane unique

About to Buy Penny Stocks? Look at These 2 Companies First

Maxx ChatskoFeb 14, 2020
soybeans in field

These Gene-Editing Pioneers Are Making Bold Bets in Agriculture

Maxx ChatskoJan 18, 2020
120 fish bowl jump

Did Cellectis Just Provide a Glimpse of the Future of Cellular Medicine?

Maxx ChatskoDec 23, 2019
564 model of DNA

This Start-up Might Be the Next Gene Editing IPO

Maxx ChatskoDec 19, 2019
IFF scientist

Why International Flavors & Fragrances, Precision BioSciences, and GameStop Slumped Today

Dan CaplingerDec 9, 2019
046 dna model

No CRISPR Required: This Forgotten Gene Editing Stock Is Up 50% in 5 Weeks

Maxx ChatskoDec 9, 2019
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Precision BioSciences

Precision BioSciences helps people with genetic diseases by fixing their DNA. It uses a tool that works like tiny scissors to repair genes. This technology aims to provide long-term cures for chronic health conditions.

Precision's Tool Kit

  • PBGENE-HBV: A gene-editing treatment designed to eliminate the source of chronic hepatitis B virus.
  • PBGENE-DMD: A therapy for Duchenne muscular dystrophy that removes specific gene sections to restore muscle function.
  • ARCUS Platform: A proprietary genome editing technology derived from nature to perform precise DNA modifications.
  • Azer-cel: An off-the-shelf cell therapy licensed to partners for treating cancer and autoimmune diseases.

Strategic Deals and Recent Progress

  • Earned a $7.5 million clinical milestone payment from TG Therapeutics in March 2026 for the azer-cel program.
  • Expanded the ELIMINATE-B clinical trial into Europe after receiving regulatory approval in April 2026.
  • Reached an agreement in 2021 to reacquire global development rights for allogeneic CAR T therapies from Servier.
  • Advanced the FUNCTION-DMD clinical trial by activating its first site and enrolling patients in April 2026.

Engineering a Smaller Solution

The company uses a proprietary platform that mimics natural DNA-cutting enzymes, which is smaller than other editing tools. This smaller size helps the treatment reach a wider range of cells and tissues in the human body.

The Financial Picture

  • Revenue reached $10.8 million in Q1 2026, up from $29,000 in Q1 2025.
  • Operating loss narrowed to $9.1 million in Q1 2026, a 59% improvement from the previous year.
  • Net loss reached $18.4 million in Q1 2026, improving by 10.3% compared to Q1 2025.
  • Free cash flow hit negative $12 million in Q1 2026, up 38.3% year-over-year.
  • Cash and cash equivalents were $99.4 million as of March 31, 2026.

Bottom Line

Precision has transitioned from a broad research firm to a clinical-stage business focused on two lead gene-editing programs. Its ability to secure partnerships and specialized regulatory designations supports its efforts to commercialize novel DNA therapies.

AI Generated • May 14, 2026

Industry

Biotechnology

Sector

Health Care

Employees

66

CEO

Michael Amoroso, EMBA

Website

www.precisionbiosciences.com

Headquarters

Durham, NC 27701, US

DTIL Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-86.77%

Net Income Margin

-96.73%

Return on Equity

-79.62%

Return on Capital

-43.08%

Return on Assets

-30.30%

Earnings Yield

-50.76%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$188.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

25.80M

Volume

1

Avg. Volume

421.11K

Financials (TTM)

Gross Profit

$45.07M

Operating Income

-$39.11M

EBITDA

-$40.42M

Operating Cash Flow

-$58.73M

Capital Expenditure

-$54.00K

Free Cash Flow

-$58.78M

Cash & ST Invst.

$101.18M

Total Debt

$28.47M

Precision BioSciences Performance Analysis

Precision BioSciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 25,098,000-78.3%
20232023-12-31USD 48,727,00094.1%
20242024-12-31USD 68,696,00041.0%
20252025-12-31USD 34,264,000-50.1%
Precision BioSciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-37.9%
Q32025-09-30-27.8%
Q42025-12-31263007.7%
Q12026-03-31-68.3%
Precision BioSciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -38.10143.6%
20232023-12-31USD -18.16-52.3%
20242024-12-31USD 1.04N/A
20252025-12-31USD -3.63N/A
Precision BioSciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-307.0%
Q32025-09-3013.6%
Q42025-12-31157.1%
Q12026-03-31-171.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$10.84M

+37272.4%

Gross Profit

$10.84M

+37272.4%

Gross Margin

100.00%

N/A

Market Cap

$188.87MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.86M

N/A

Employees

66

N/A

Net Income

-$18.44M

+10.3%

EBITDA

-$17.49M

+10.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$101.18M

+31.0%

Total Debt

$28.47M

-4.3%

Accounts Receivable

$4.00M

+99900.0%

Inventory

$0.00

N/A

Long Term Debt

$26.91M

-5.2%

Short Term Debt

$1.56M

+14.1%

Return on Assets

-30.30%

N/A

Return on Invested Capital

-28.73%

N/A

Free Cash Flow

-$11.96M

+38.3%

Operating Cash Flow

-$11.94M

+37.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
STROSutro Biopharma, Inc.
$23.40+1.74%
CNTBConnect Biopharma Holdings Limited
$2.20-0.45%
ARTVArtiva Biotherapeutics, Inc.
$10.02+0.20%
RPTXRepare Therapeutics Inc.
$2.65+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%
NOKNokia
$10.30-0.03%

Questions About DTIL

What is the current price of Precision BioSciences?

Precision BioSciences is trading at $7.32 per share.

What is the 52-week range for Precision BioSciences?

Over the past 52 weeks, Precision BioSciences has traded between $3.53 and $9.62.

How much debt does Precision BioSciences have?

As of the most recent reporting period, Precision BioSciences reported total debt of $28.47M.

How much cash does Precision BioSciences have on hand?

Precision BioSciences reported $99.37M in cash and cash equivalents in its most recent financial results.

What is Precision BioSciences’s dividend yield?

Precision BioSciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services